A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2004
11/25/2004	US20040235863 As stimulators for soluble guanylate cyclase and to their use as agents in the therapy of cardiovascular diseases, hypertonicity, thrombo-embolic diseases and ischemia, sexual dysfunction or inflammations and for the treatment of diseases of the central nervous system
11/25/2004	US20040235859 Novel piperazine derivatives
11/25/2004	US20040235858 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
11/25/2004	US20040235854 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity
11/25/2004	US20040235849 For therapy and prophylaxis of states of pain
11/25/2004	US20040235848 Phenylalanine derivatives
11/25/2004	US20040235845 Use of phosphodiesterase iv inhibitors
11/25/2004	US20040235843 For therapy of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy
11/25/2004	US20040235838 Use of 2-alkoxyphenol-substituted imidazotriazinones
11/25/2004	US20040235837 Method for treating fibrotic diseases or other indications IE
11/25/2004	US20040235830 Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases
11/25/2004	US20040235828 For therapy and prophylaxis of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases
11/25/2004	US20040235825 Administering compounds such as N-[4-[2-[2-(1-naphthyl)propanoylamino]phenyl]butanoyl]-(3,5-dimethylisoxazol-4-yl)sulfonamide for prophylaxis and therapy of pain, allodynia, hyperalgesia, pruritus, urticaria, atopic dermatitis, contact dermatitis, allergic conjunctivitis, asthma, rhinitis, sneeze
11/25/2004	US20040235818 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/25/2004	US20040235816 Administering compounds such as 1-benzhydryl-3-[(methylsulfonyl)(phenyl)methylene]azetidine for therapy of schizophrenia, Parkinson's disease, and Alzeimer's disease
11/25/2004	US20040235809 Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure
11/25/2004	US20040235808 Administering compounds such as 17 beta -[4-(dimethylamino)-benzoyloxy]-androst-4-en-3-one for modulating a function mediated by the androgen receptor in a tissue selective manner
11/25/2004	US20040235802 Combinations comprising cox-2-inhibitors and aspirin
11/25/2004	US20040235799 Use of a compound with a negatively charged domain of radicals for the treatment of restenosis
11/25/2004	US20040235786 Highly purified antiendotoxin compound
11/25/2004	US20040235757 Anticarcinogenic and antimetastasis agents; leukemia or Hodgkin's disease.
11/25/2004	US20040235754 Dipeptide derivatives
11/25/2004	US20040235740 Administered as antitumor, antimetastasis, anticarcinogenic and/or wound healing agent; tissue regeneration
11/25/2004	US20040235727 Comprising H 376/95, sodium dodecyl sulphate, and a polymer selected from hydroxypropyl methylcellulose, hydroxyethyl cellulose, and polyoxyethylene oxide; use in treatment of thromboembolism
11/25/2004	US20040235720 May also be used in combination with an interferon for treatment and/or prevention of diseases such as traumatic nerve injury, stroke, demyelinating diseases of the CNS or PNS, neuropathies and neurodegenerative diseases
11/25/2004	US20040235718 Use of Afamin, in particular in combination with vitamin E, is for treatment of oxidative stress; treatment of Alzheimer's Disease, Huntington's Disease or amyotropic lateral sclerosis
11/25/2004	US20040235710 Comprising a GLP-1 compound and an acylated basal insulin or a pI shifted basal insulin; can be used to treat diseases such as non-insulin dependent diabetes mellitus and insulin dependent diabetes mellitus, hyperglycemia, obesity
11/25/2004	US20040235163 Comprises regulatory agent which prevents apoptosis and/or cardiac oxidative stress in myocardial tissues; identifying modulators of atp sensitive potassium channels
11/25/2004	US20040235123 Transgenic escherichia for use as bioreactor in fermentation of alpha-lipoic acid for use in animal feeds, medicines and cosmetics
11/25/2004	US20040235006 Chemical compounds
11/25/2004	US20040234674 Artichoke leaf extracts
11/25/2004	US20040234631 Composition comprising soy and use thereof in the provention and/or treatment of various diseases
11/25/2004	US20040234630 Beneficial effect of distiller's grain in cardiovascular disease
11/25/2004	US20040234617 Water extraction; centrifuging; separation; cooling; freeze drying; hypotensive agents
11/25/2004	US20040234572 Preparation of sustained release pharmaceutical composition
11/25/2004	US20040234544 Formulation containing (lyso-)phosphatidylserine for the prevention and treatment of stress states in warm blooded animals
11/25/2004	US20040234527 Peptides for use as translocation factors
11/25/2004	US20040234523 Antiischemic agents; synergistic mixture of interleukin inhibitor and tumor necrosis factor antagonist
11/25/2004	US20040234520 Uses for Eph receptor antagonists and agonists
11/25/2004	US20040234454 Pathological tissue detection and treatment employing targeted benzoindole optical agents
11/25/2004	CA2526025A1 Preventive and/or remedy for diseases accompanied by tissue destruction
11/25/2004	CA2525909A1 Novel stem cell derived from adult tissue and use thereof
11/25/2004	CA2525522A1 C1 inhibitor with short half-life for transient treatment
11/25/2004	CA2524780A1 Compounds for treatment of inflammation, diabetes and related disorders
11/25/2004	CA2523978A1 Crystal of benzimidazole derivative and process for producing the same
11/25/2004	CA2523746A1 Method of treating atrial fibrillation or atrial flutter
11/24/2004	EP1479768A1 Novel screening method
11/24/2004	EP1479671A1 Pyrimidinone compounds
11/24/2004	EP1479670A1 Novel fused ring indazole compounds
11/24/2004	EP1479666A1 Ester compound and medicinal use thereof
11/24/2004	EP1479395A1 Modified factor VII
11/24/2004	EP1478764A2 Humanized collagen antibodies and related methods
11/24/2004	EP1478762A2 Nucleic acid-associated proteins
11/24/2004	EP1478758A1 Polymorphisms in elastin, fibrillin, and related genes as predisposing to restenosis and to atherosclerosis
11/24/2004	EP1478745A2 Kinases and phosphatases
11/24/2004	EP1478730A2 RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/24/2004	EP1478660A2 KAPPA−PVIIA−RELATED CONOTOXINS AS ORGAN PROTECTANTS
11/24/2004	EP1478659A2 Biologically active peptides
11/24/2004	EP1478656A2 Oligonucleotide compositions with enhanced efficiency
11/24/2004	EP1478648A2 Phosphorus-containing compounds uses thereof
11/24/2004	EP1478645A2 Quinolinone derivatives for treating cell proliferation related disorders
11/24/2004	EP1478640A1 Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives
11/24/2004	EP1478631A1 Therapeutic compounds
11/24/2004	EP1478627A1 Method
11/24/2004	EP1478624A1 Chemical compounds
11/24/2004	EP1478620A1 Phenethanolamine derivatives for treatment of respiratory diseases
11/24/2004	EP1478613A2 Substituted 10-aryl-11h-benzo[b]fluorenes and 7-aryl-5,6-dihydro-benz[a]anthracenes for selective effects on estrogen receptors
11/24/2004	EP1478393A2 Anti-pathogen treatements
11/24/2004	EP1478387A1 Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences
11/24/2004	EP1478383A2 Compositions and methods for promoting myocardial and peripheral angiogenesis
11/24/2004	EP1478374A1 Formulations comprising psychotropic drugs and selenium
11/24/2004	EP1478362A1 A combination treatment for acute myocardial infarction
11/24/2004	EP1478361A2 Arylsulfone derivatives
11/24/2004	EP1478358A1 Aryl ureas with angiogenesis inhibiting activity
11/24/2004	EP1478357A2 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
11/24/2004	EP1478354A2 Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection
11/24/2004	EP1478353A1 Sustained release pharmaceutical composition
11/24/2004	EP1478352A1 Pharmaceutical dosage form and method for the production thereof
11/24/2004	EP1478236A2 Targeted retrograde gene delivery to motor neurons
11/24/2004	EP1318976B1 Substituted aminopropoxyaryl derivatives useful as agonists for lxr
11/24/2004	EP1309556B1 Amlodipine fumarate
11/24/2004	EP1307201B1 Selective pde 2 inhibitors, used as medicaments for improving cognition
11/24/2004	EP1305306B1 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
11/24/2004	EP1285000B1 Adnf mixtures for enhancing learning and memory
11/24/2004	EP1272201B1 Use of compatible solutes as substances having free radical scavenging properties
11/24/2004	EP1267841B1 Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine
11/24/2004	EP1200406B1 Cyclic amides and imides having selective antagonist activity at alpha-1d adrenergic receptor
11/24/2004	EP1175214B1 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/24/2004	EP1159265B1 C-16 unsaturated fp-selective prostaglandins analogs
11/24/2004	EP1144673A4 Methods of screening protease inhibitors, of inducing mice susceptible to hiv protease inhibitor-induced dyslipidemia, and genes associated therewith
11/24/2004	EP1107971B1 Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them
11/24/2004	EP0946185B1 PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND
11/24/2004	EP0688220B1 Use of dhea and derivatives thereof for the manufacture of a medicament for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
11/24/2004	CN1549824A Peptidic compounds selectively binding to p-selectin
11/24/2004	CN1549817A Pyrrolo pyrimidines, process for their preparation, their use and pharmaceutical compositions containing them
11/24/2004	CN1549816A N-aroyl cyclic amine derivatives as orexin receptor antagonists
11/24/2004	CN1549814A Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
11/24/2004	CN1549813A Pyrimidineamines as angiogenesis modulators
11/24/2004	CN1549812A Pyrazole compounds useful as protein kinase inhibitors.
11/24/2004	CN1549803A 维生素d的类似物 Analogs of vitamin d

1 ... 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 ... 1595